secwatch.observer — SEC 8-K summary
======================================

Issuer:     Rallybio Corp (RLYB)
CIK:        0001739410
Form:       8-K
Filed at:   2025-08-07T23:59:59+00:00
Accession:  0001739410-25-000108
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rallybio Q2 net loss $9.7M, sells REV102 to Recursion for $25M; RLYB116 data Q3/Q4 2025
--------------------------------------------------------------------------------

- Net loss of $9.7M ($0.22/share) vs $16.2M in Q2 2024; revenue $0.2M.
- Sold REV102 to Recursion for up to $25M, including $7.5M upfront equity; cash runway extended into mid-2027.
- RLYB116 confirmatory PK/PD study dosing started; Cohort 1 and Cohort 2 topline data expected Q3 and Q4 2025.
- RLYB212 program discontinued after Phase 2 PK data missed target concentrations.
- Cash, equivalents and marketable securities $45.7M at June 30, 2025; with REV102 payment, runway into mid-2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1739410/000173941025000108/0001739410-25-000108-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1739410/000173941025000108/rlyb-20250807.htm
  HTML page:      https://secwatch.observer/filing/0001739410-25-000108

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer